The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The OPTec study: evaluating outpatient step-up administration of teclistamab in pts with R/R myeloma
Robert Rifkin, MD, Rocky Mountain Cancer Centers, Denver, CO, presents the first results of the OPTec trial (NCT05972135), a Phase II study evaluating outpatient (OP) step-up administration of teclistamab (Tec) in patients with relapsed/refractory (R/R) multiple myeloma (MM). Prophylactic tocilizumab and corticosteroids are given to mitigate cytokine release syndrome (CRS) and neurotoxicity in patients and make OP administration of bispecific antibodies safe and feasible. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
